Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy—a national population-based study
Open Access
- 6 April 2020
- journal article
- research article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 18 (1) , 1-8
Abstract
Background: Comprehensive readmission morbidity studies after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are scarce. This study aimed to investigate readmissions and in-hospital morbidity after CRS and HIPEC. Methods: The national in-hospital patient register was used to identify patients via the HIPEC ICD code JAQ10 2004–2014. Data were retrieved from the index CRS/HIPEC treatment and from all HIPEC-related readmissions within 6 months. Univariate/multivariate logistical analyses were performed to identify risk factors for reinterventions and readmissions. Results: A total of 519 patients (mean age 56 years) had a mean hospital stay of 27 days. Within 6 months, 150 readmissions for adverse events were observed in 129 patients (25%) with 67 patients requiring an intervention (13%). Totally 179 patients (34%) required a reintervention during the first 6 months with 85 (16%) requiring a reoperation. Of these 179 patients, 83 patients (46%) did not undergo the intervention at the HIPEC centre. Gastric resection was the only independent risk factor for in-hospital intervention, and advanced age for readmission. Conclusion: Morbidity causing HIPEC-related readmission was higher than expected with almost half of the interventions occurring outside the HIPEC centre. Gastric resection and high age are independent predictors of morbidity and readmission.Keywords
Funding Information
- Cancerfonden (170206)
This publication has 36 references indexed in Scilit:
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerNew England Journal of Medicine, 2018
- Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal OriginAnnals of Surgical Oncology, 2013
- Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decadesBritish Journal of Cancer, 2013
- Factors Influencing Readmission After PancreaticoduodenectomyAnnals of Surgery, 2012
- Treatment‐related morbidity and toxicity of CRS and oxaliplatin‐based HIPEC compared to a mitomycin and doxorubicin‐based HIPEC protocol in patients with peritoneal carcinomatosis: A matched‐pair analysisJournal of Surgical Oncology, 2012
- Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case–control studyAnnals of Oncology, 2011
- Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?Annals of Surgery, 2009
- Hyperthermic Intraperitoneal Chemotherapy After Extensive Cytoreductive Surgery in Patients with Primary Advanced Epithelial Ovarian Cancer: Interim Analysis of a Phase II StudyAnnals of Surgical Oncology, 2009
- The eligibility for local-regional treatment of peritoneal surface malignancyJournal of Surgical Oncology, 2008
- Peritonectomy ProceduresAnnals of Surgery, 1995